ArticleFrontiers in pharmacology2026
Calycosin protects from histopathological and ultrastructural changes in ethanol-induced liver injury and exhibits predicted binding affinity to TNF-α/NF-κB/HIF-1α proteins.
Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background/objectives: Liver fibrosis is the consequence of the wound-healing response of the liver to frequent injury. Calycosin is a flavonoid, which has been documented for its hepatoprotective properties. The aim of this study was to evaluate the hepatoprotective action of calycosin in a model of ethanol-induced liver injury (EILI) in rats. For mechanistic insights, we aimed to measure tumor necrosis factor-α (TNF-α), nuclear factor-κB (NF-κB), and hypoxia-inducible factor-1 alpha (HIF-1α) protein levels in liver samples and evaluate the ability of calycosin to bind these pathologic molecules. Methods: Network pharmacology and molecular docking were performed for discovering the interacting target proteins. Forty male rats were assigned into five groups: 1) the vehicle, 2) the calycosin per se group, 3) the EILI control group, and 4) and 5) the EILI + calycosin (5 or 10 mg/kg) groups. The liver homogenates were used for ELISA measurement of TNF-α, NF-κB, and HIF-1α. Furthermore, liver specimens were used for histopathological and ultrastructural investigations. Results: The network pharmacology study confirmed the role of TNF-α/NF-κB/HIF-1α signaling in EILI, and molecular docking explored the possible interaction between calycosin and these three molecules (docking score = -7.6, -7, and -7.6 kcal/mol). The rat study showed that calycosin was able to attenuate histopathological and ultrastructural changes in rat livers, reduce collagen accumulation, and prevent the increases shown in liver enzyme activities (2.17-fold for ALT and 2.26-fold for AST). Conclusion: Thus, these integrated
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.